企業概要
Qiagen N.V. operates within the healthcare sector, specifically focusing on the diagnostics and research industry where it provides sample-to-insight solutions that convert biological samples into molecular data globally. The firm specializes in offering consumables for sample technology, such as kits for nucleic acid stabilization, purification, and processing for genotyping and gene analysis. This entity maintains a substantial operational scale with a reported market capitalization of $8.05 billion and a trailing twelve-month revenue of $2.09 billion. Supporting this financial footprint, the company employs 5,654 individuals worldwide to execute its global supply chain and research support functions. The combination of an $8.05 billion market cap and $2.09 billion in annual revenue indicates that Qiagen holds a significant position within the specialized diagnostics market, reflecting strong investor confidence in its technological platform and global distribution network.
財務健全性
Qiagen N.V. reported a trailing twelve-month revenue of $2.09 billion, generating a net income of $424.88 million and an EBITDA of $728.29 million. The substantial gap between the $2.09 billion in revenue and the $424.88 million in net income reveals a cost structure characterized by significant operating expenses, including research and development costs, sales and marketing expenditures, and general administrative overhead that consume approximately 80% of top-line growth before reaching the bottom line. The company generated free cash flow of $257.10 million, which demonstrates a positive ability to convert earnings into cash and provides the financial flexibility necessary for capital expenditures, share repurchases, or strategic acquisitions without immediate reliance on external financing. Profitability analysis shows a gross margin of 66.4%, indicating high pricing power or efficient manufacturing costs relative to the cost of goods sold, while an operating margin of 27.4% and a profit margin of 20.3% reflect the company's ability to effectively manage overhead costs and translate gross profits into net earnings. Regarding liquidity and leverage, the balance sheet shows cash holdings of $1.10 billion against total debt of $1.83 billion, resulting in a debt-to-equity ratio of 48.56%, which suggests a moderately leveraged balance sheet where interest obligations are nearly half the size of shareholders' equity. The current ratio stands at 3.90, a metric that indicates strong short-term liquidity, meaning the company possesses nearly four times the current assets required to cover its current liabilities without needing to sell long-term assets or raise additional capital. Return metrics further illuminate management effectiveness, with a return on equity of 11.6% showing efficient generation of profit from shareholder investments and a return on assets of 5.8% indicating moderate efficiency in utilizing the asset base to generate earnings.
バリュエーション評価
Qiagen N.V. currently trades with a trailing P/E ratio of 19.15 and a forward P/E of 14.14, and the difference between these two metrics implies that the market expects earnings growth that will lower the forward multiple relative to the historical trailing multiple. The price-to-book ratio is stated at 2.13, which indicates that the stock is trading at a market premium of over twice its book value per share, reflecting the market's valuation of intangible assets like intellectual property and brand strength that are not captured on the balance sheet. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 3.85 and an EV/EBITDA of 12.06, suggesting that investors are willing to pay a significant multiple of sales and enterprise value relative to operating cash flow. Price movement context is provided by a 52-week high of $57.82 and a 52-week low of $38.13, and calculating the position relative to this range shows the stock has experienced volatility but remains within a defined historical band over the past year. The beta value is 0.71, which explains that the stock's price volatility is historically lower than the broader market, indicating that the stock tends to move less drastically than the overall market index during periods of rising or falling prices.
Growth & Income
Qiagen N.V. reported a year-over-year revenue growth of 3.7% and an earnings growth of 21.9%, and the fact that earnings are growing significantly faster than revenue implies an improving cost structure, operational leverage, or a shift in the product mix toward higher-margin offerings. The company offers a dividend yield of 0.7% and maintains a payout ratio of 12.9%, and this low payout ratio suggests that the company retains the majority of its earnings to fund operations, R&D, and growth initiatives rather than distributing all profits to shareholders. Given the low payout ratio of 12.9%, the company prioritizes reinvesting earnings into its core diagnostics and research business to sustain long-term growth rather than focusing on high dividend payouts. Overall, the growth and income profile presents a scenario of modest top-line expansion accompanied by strong earnings acceleration and a conservative dividend policy that preserves capital for future strategic opportunities.